N-[5-(环丙基氨基)-7-(三氟甲基)[1,2,4]三唑并[1,5-a]吡啶-2-基]-3-吡啶甲酰胺 | 1124381-43-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并吡啶类
• 中文名称: N-[5-(环丙基氨基)-7-(三氟甲基)[1,2,4]三唑并[1,5-a]吡啶-2-基]-3-吡啶甲酰胺
• 英文名称: MSC 2032964A
• 英文别名: N-(5-(cyclopropylamino)-7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)nicotinamide；N-[5-(cyclopropylamino)-7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]pyridine-3-carboxamide
• CAS: 1124381-43-6
• 化学式: C₁₆H₁₃F₃N₆O
• 分子量: 362.314
• InChiKey: XUKGFHHTSUKORV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  84.2
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  N-[5-chloro-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide 、 环丙胺 生成 N-[5-(环丙基氨基)-7-(三氟甲基)[1,2,4]三唑并[1,5-a]吡啶-2-基]-3-吡啶甲酰胺
  参考文献：
  名称：

  TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS

  摘要：

  本发明涉及公式（I）的三唑吡啶化合物，其用作药物，用于治疗自身免疫性疾病、炎症性疾病、心血管疾病和/或神经退行性疾病以及其制备过程。

  公开号：

  US20120238565A1

文献信息

• [EN] TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS<br/>[FR] COMPOSÉS DE TRIAZOLOPYRIDINE ET LEUR UTILISATION COMME INHIBITEURS DE ASK
  申请人：SERONO LAB

  公开号：WO2009027283A1

  公开（公告）日：2009-03-05

  The present invention relates to triazolopyridine compounds according to Formula (I), their use as medicament, for treating autoimmune disorders, inflammatorydiseases, cardiovascular disceases and/or neurodegenerative diseases and a process for their preparation.

  本发明涉及三唑吡啶化合物，其化学式为（I），其用作药物，用于治疗自身免疫性疾病、炎症性疾病、心血管疾病和/或神经退行性疾病，以及其制备方法。
• Triazolopyridine Compounds and Their Use as Ask Inhibitors
  申请人：Swinnen Dominique

  公开号：US20100197681A1

  公开（公告）日：2010-08-05

  The present invention relates to triazolopyridine compounds according to Formula (I), their use as medicament, for treating autoimmune disorders, inflammatory diseases, cardiovascular diseases and/or neurodegenerative diseases and a process for their preparation.

  本发明涉及按照公式（I）的三唑吡啶化合物，它们的用途是作为药物治疗自身免疫性疾病、炎症性疾病、心血管疾病和/或神经退行性疾病以及它们的制备方法。
• Triazolopyridine compounds and their use as ask inhibitors
  申请人：Merck Serono SA

  公开号：US08263595B2

  公开（公告）日：2012-09-11

  The present invention relates to triazolopyridine compounds according to Formula (I), their use as medicament, for treating autoimmune disorders, inflammatory diseases, cardiovascular diseases and/or neurodegenerative diseases and a process for their preparation.

  本发明涉及三唑吡啶化合物，其化学式为（I），它们的用途是作为药物治疗自身免疫性疾病、炎症性疾病、心血管疾病和/或神经退行性疾病，并提供其制备方法。
• COMBINATION THERAPIES WITH FARNESOID X RECEPTOR (FXR) MODULATORS
  申请人：Akarna Therapeutics, Ltd.

  公开号：US20200397798A1

  公开（公告）日：2020-12-24

  Described herein are methods of treating a metabolic disorder in an individual in need thereof, comprising co-administering to the individual a therapeutically effective amount of an FXR modulator, and at least one second agent that is an CCR2/CCR5 antagonist, ASK1 inhibitor, DPP-IV inhibitor, caspase protease inhibitor, SGLT2 inhibitor, acetyl-CoA carboxylase (ACC) inhibitor, diacylglycerol acyltransferase-1 inhibitor, sodium-bile acid cotransporter-inhibitor, TLR-4 antagonist, PPAR alpha/delta agonist, or GLP-1 agonist, or a combination thereof.
• Combination Therapy for Modulating Bile Acid Homeostasis and Treatment of Bile Acid Disorders and Diseases
  申请人：NGM Biopharmaceuticals, Inc.

  公开号：US20200390858A1

  公开（公告）日：2020-12-17

  Provided herein are methods of modulating bile acid homeostasis or treating a bile acid-related or associated disorder, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), in combination with agents effective in modulating bile acid homeostasis or treating a bile acid-related or associated disorder.